DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
CIREVETMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CIREVETMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GATIPOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
GATIPOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
85V55ZLV2Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MUZASTOTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MUZASTOTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RIPERTAMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Unknown
RIPERTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
URS0374MIV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LORIGERLIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LORIGERLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUNLEKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LUNLEKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CADONILIMAB
2
Antibody
Investigational
Unknown
Unknown
Lung Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Nasopharyngeal Neoplasms; Neoplasms; Uterine Cervical Neoplasms
Cytotoxic T-lymphocyte protein 4 inhibitor
CADONILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SGN-15
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Prostatic Neoplasms
Lewis Y antigen binding agent
SGN-15
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LANERKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LANERKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DANVILOSTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DANVILOSTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NEZASTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
NEZASTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
8H9 131I
2
Antibody
Investigational
Unknown
Unknown
Peritoneal Neoplasms; Meningeal Carcinomatosis; Neuroblastoma
CD276 antigen binding agent
8H9 131I
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VOLAGIDEMAB
2
Antibody
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Hyperglycemia; Diabetes Mellitus, Type 1
Glucagon receptor inhibitor
VOLAGIDEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
77JYS6UZ0M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-4721
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Digestive System Diseases
Prostate stem cell antigen inhibitor
MK-4721
×
Maximum Phase:
2
First Approval:
None
UNII:
L0505LPC7O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIPAVIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SIPAVIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAMIDANLUMAB TESIRINE
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hodgkin Disease; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
DNA cross-linking agent
CAMIDANLUMAB TESIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
LYJ1AEJ9YH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZERUTAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
AZERUTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BB-10901
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Small Cell Lung Carcinoma
Neural cell adhesion molecule 1 binding agent
BB-10901
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GC1118
2
Antibody
Investigational
Unknown
Unknown
Glioblastoma; Stomach Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
GC1118
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CLENOLIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
CLENOLIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SCH-708980
2
Antibody
Investigational
Unknown
Unknown
Leishmaniasis
Interleukin-10 inhibitor
SCH-708980
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VOLENRELAXIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VOLENRELAXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DONZAKIMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DONZAKIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASCRINVACUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Mesothelioma
Serine/threonine-protein kinase receptor R3 inhibitor
ASCRINVACUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
716FQ5REVO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABIPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ABIPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PD-360324
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Sarcoidosis, Pulmonary
Macrophage colony-stimulating factor 1 inhibitor
PD-360324
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RENVISTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
RENVISTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DALNICASTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DALNICASTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROCONKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ROCONKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MICVOTABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MICVOTABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UCENPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
UCENPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2541546
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LY2541546
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MELRILIMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
MELRILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
26C72EGQ3G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SETRUSUMAB
2
Antibody
Investigational
Unknown
Unknown
Hypophosphatasia; Kidney Diseases; Osteogenesis Imperfecta
Sclerostin inhibitor
SETRUSUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FPW3780T3E
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GREZIPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
GREZIPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
21
22
23
24
25
26
27
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA